Furthermore, the MAPK pathway could be targeted with new therapeutics, such as specific inhibitors of KRAS G12C mutations that have recently demonstrated meaningful anti-cancer activity in lung cancer with KRAS G12C mutations. This evidence concerns the gene KRAS and lung carcinoma.